These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35624169)

  • 61. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
    Williams WW; Lu PJ; O'Halloran A; Kim DK; Grohskopf LA; Pilishvili T; Skoff TH; Nelson NP; Harpaz R; Markowitz LE; Rodriguez-Lainz A; Bridges CB;
    MMWR Surveill Summ; 2016 Feb; 65(1):1-36. PubMed ID: 26844596
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment.
    Patterson BJ; Myers K; Stewart A; Mange B; Hillson EM; Poulos C
    Expert Rev Vaccines; 2021 Jun; 20(6):729-741. PubMed ID: 33902368
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A systematic review of reference pricing: implications for US prescription drug spending.
    Lee JL; Fischer MA; Shrank WH; Polinski JM; Choudhry NK
    Am J Manag Care; 2012 Nov; 18(11):e429-37. PubMed ID: 23198752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States.
    Kreps S; Kriner DL
    PLoS One; 2022; 17(3):e0265011. PubMed ID: 35353846
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview.
    Verghese NR; Barrenetxea J; Bhargava Y; Agrawal S; Finkelstein EA
    J Mark Access Health Policy; 2019; 7(1):1601060. PubMed ID: 31007877
    [No Abstract]   [Full Text] [Related]  

  • 67. Improving global vaccine accessibility.
    Hill AB; Kilgore C; McGlynn M; Jones CH
    Curr Opin Biotechnol; 2016 Dec; 42():67-73. PubMed ID: 26994376
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.
    Kumraj G; Pathak S; Shah S; Majumder P; Jain J; Bhati D; Hanif S; Mukherjee S; Ahmed S
    Hum Vaccin Immunother; 2022 Dec; 18(1):2020529. PubMed ID: 35086416
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Jeremiah Metzger Lecture. Vaccine prophylaxis today: its science, application and politics.
    Douglas RG
    Trans Am Clin Climatol Assoc; 1998; 109():185-96; discussion 196-8. PubMed ID: 9601137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices.
    Jadhav S; Gautam M; Gairola S
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():37-44. PubMed ID: 24476201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A top-five list for emergency medicine: a pilot project to improve the value of emergency care.
    Schuur JD; Carney DP; Lyn ET; Raja AS; Michael JA; Ross NG; Venkatesh AK
    JAMA Intern Med; 2014 Apr; 174(4):509-15. PubMed ID: 24534899
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.
    Hayman B; Bowles A; Evans B; Eyermann E; Nepomnyashchiy L; Pagliusi S
    Vaccine; 2021 Feb; 39(8):1190-1194. PubMed ID: 33487466
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Equity in Pharmaceutical Pricing and Reimbursement: Crossing the Income Divide in Asia Pacific.
    Daems R; Maes E; Glaetzer C
    Value Health Reg Issues; 2013 May; 2(1):160-166. PubMed ID: 29702846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Economic aspects of vaccines and immunizations.
    Hinman AR
    C R Acad Sci III; 1999 Nov; 322(11):989-94. PubMed ID: 10646095
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development: description of a successful public-private sector international collaboration.
    Bronnenkant L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S311-3. PubMed ID: 7865329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.